Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, August 6, 2021
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
[ Fri, Aug 06th 2021
] - WOPRAI
Gena Wang Maintained (BCRX) at Buy with Increased Target to $21 on, Aug 6th, 2021
Gena Wang of Barclays, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Buy with Increased Target from $20 to $21 on, Aug 6th, 2021.
Gena has made no other calls on BCRX in the last 4 months.
There is 1 other peer that has a rating on BCRX. Out of the 1 peers that are also analyzing BCRX, 0 agree with Gena's Rating of Hold.
This is the rating of the analyst that currently disagrees with Gena
- Brian Cheng of "Cantor Fitzgerald" Initiated at Buy and Held Target at $21 on, Tuesday, August 3rd, 2021
